Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | CHIEF SCIENTIFIC OFFICER | July 03, 2024 | July 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date July 03, 2024 · Filed July 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 62,024 |
Reported balance
After 2024-07-03 transaction · row 1
1 source rowRow 1 · 2024-07-03 · Sale · Disposed 779 · Balance 62,024 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy GRAT | 7,000 |
Reported balance
Holding disclosure · report date 2024-07-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2024 Filed Jul 8, 2024 18:55 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 779 | $19.64 | $15,299.56 |
DisclosureSEC source: 0001415889-24-019385 · form4-07082024_060705.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,024 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 790 | $23.81 | $18,809.90 |
DisclosureSEC source: 0001415889-24-010414 · form4-04052024_040430.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,803 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 18:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,640 | $17.50 | $46,200.00 |
DisclosureSEC source: 0001209191-24-000888 · doc4.xml · nonDerivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,593 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 18:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000888 · doc4.xml · derivative · entry 4 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Ordinary Shares · 56,000 shares Expires 2034-01-02 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 18:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000888 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,233 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 17:49 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 272 | $20.00 | $5,440.00 |
DisclosureSEC source: 0001209191-23-052253 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,233 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 16:50 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 336 | $25.10 | $8,433.60 |
DisclosureSEC source: 0001209191-23-041570 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,505 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:43 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 319 | $21.11 | $6,734.09 |
DisclosureSEC source: 0001209191-23-023352 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,841 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-23-002193 · doc4.xml · derivative · entry 4 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2033-01-03 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,817 | $29.06 | $52,802.02 |
DisclosureSEC source: 0001209191-23-002193 · doc4.xml · nonDerivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,160 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002193 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,977 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $60.87 | $0.00 |
DisclosureSEC source: 0001209191-22-001814 · doc4.xml · derivative · entry 3 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2023 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001814 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,477 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2023 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:01 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,477 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071008 · doc4.xml · derivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,927 Underlying: Ordinary Shares · 15,477 shares Expires 2029-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:01 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 15,477 | $14.00 | $216,678.00 |
DisclosureSEC source: 0001209191-21-071008 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 16:16 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,178 | $45.10 | $98,227.80 |
DisclosureSEC source: 0001209191-21-059375 · doc4.xml · nonDerivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 16:16 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,188 | $45.00 | $53,460.00 |
DisclosureSEC source: 0001209191-21-059375 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,178 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 16:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,955 | $45.01 | $87,994.55 |
DisclosureSEC source: 0001209191-21-056655 · doc4.xml · nonDerivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,366 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,000 | $45.00 | $135,000.00 |
DisclosureSEC source: 0001209191-21-056655 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 16:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-21-054789 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 18:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0001209191-21-046997 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-21-024641 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 19:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 217 | $28.00 | $6,076.00 |
DisclosureSEC source: 0001209191-21-021150 · doc4.xml · nonDerivative · entry 3 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 19:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 283 | $29.00 | $8,207.00 |
DisclosureSEC source: 0001209191-21-021150 · doc4.xml · nonDerivative · entry 2 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,538 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 19:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 9,500 | $28.48 | $270,560.00 |
DisclosureSEC source: 0001209191-21-021150 · doc4.xml · nonDerivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,821 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 70,500 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001372 · doc4.xml · derivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 Underlying: Common Stock · 70,500 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 4, 2022 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:59 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-001944 · doc4.xml · derivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter. Read SEC document |
| June 28, 2019 Filed Apr 27, 2020 16:44 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 177,404 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025811 · doc4a.xml · derivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,404 Underlying: Ordinary Shares · 177,404 shares Expires 2029-06-28 F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:24 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 177,404 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-032907 · a4.xml · derivative · entry 1 Keen Nicholas · CIK 0001776881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,404 Underlying: Ordinary Shares · 177,404 shares Expires 2029-05-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.